FCTC at 21: One Billion Smokers Later

Twenty-one years after the adoption of the World Health Organisation’s global tobacco treaty, combustible cigarettes remain legally sold in virtually every country on Earth. More than a billion people still smoke. In parts of Africa and Southeast Asia, population growth has offset declines in prevalence, meaning the absolute number of smokers has barely changed. Illicit trade remains entrenched despite protocols and enforcement efforts. In several high-income countries, long celebrated for their tobacco control leadership, smoking declines have slowed or stalled.

If this is an evidence-based blueprint, why are outcomes so uneven?

The treaty in question, the World Health Organisation Framework Convention on Tobacco Control, was adopted in 2003 and entered into force in 2005. It was the first global public health treaty, and it has achieved near universal adoption. On paper, it is one of the most successful multilateral health agreements ever negotiated. Its core package of measures, often summarised as taxation, advertising bans, smoke-free laws, graphic warnings and demand reduction strategies, reshaped tobacco policy worldwide.

Yet its intellectual architecture reflects the era in which it was conceived. The early 2000s were defined by a single overwhelming source of nicotine-related harm: the cigarette. The strategy was therefore built around constraining supply, deterring demand and marginalising the tobacco industry. It is assumed that reducing consumption meant reducing nicotine use primarily by discouraging and penalising it.

What it did not meaningfully incorporate was risk differentiation. It did not distinguish clearly between combustion and non-combustion. It treated tobacco and, increasingly in later interpretations, nicotine itself as a unified policy problem.

That omission now matters.

The nicotine landscape of 2026 bears little resemblance to that of 2005. Electronic cigarettes, heated tobacco products and other non-combustible alternatives now exist at scale. The scientific consensus remains contested in places, but there is broad agreement that combustion is the primary driver of smoking-related disease. When tobacco burns, it generates thousands of chemicals, many of them toxic. Remove combustion, and the risk profile changes significantly.

This distinction is not trivial. It is foundational.

In countries that have allowed regulated access to lower-risk alternatives, smoking has in many cases declined more rapidly. In the United Kingdom, where vaping has been integrated into smoking cessation guidance and publicly acknowledged as substantially less harmful than smoking, cigarette use has continued to fall to historic lows. In Sweden, where oral nicotine products have long been culturally embedded, smoking prevalence has dropped to levels that approach a de facto smoke-free society.

By contrast, in jurisdictions that have restricted, medicalised or effectively prohibited consumer access to these alternatives, illicit markets have often expanded. Consumers do not simply disappear when legal access is narrowed. Demand shifts underground. The result is an enforcement-driven model that can consume increasing regulatory energy without necessarily delivering proportionate health gains.

Yet global messaging continues to focus on “tobacco-free” futures rather than smoke-free outcomes. The aspiration is understandable. Few would argue against a world with fewer diseases and fewer premature deaths. But framing matters. A tobacco-free goal can blur the distinction between the product that causes most harm and other nicotine delivery systems that may carry substantially lower risk.

The question is not whether cigarettes are deadly. They are. The question is whether policy frameworks designed before the advent of scalable harm reduction technologies are sufficiently adaptable to incorporate them.

There is also a subtle but important tension between celebrating near-universal treaty adoption and equating adoption with effectiveness. Ratification is a diplomatic achievement. It signals consensus and commitment. But signing a treaty is not the same as optimising policy. A wide embrace can just as easily entrench orthodoxy as encourage innovation. Once a framework becomes the global default, deviation can be framed as heresy rather than experimentation.

Public health institutions are understandably cautious. They operate in environments shaped by corporate misconduct, historical deception and legitimate fears of industry influence. The instinct to close regulatory gaps rather than open them is deeply embedded. However, caution can evolve into rigidity. When new technologies emerge, the question should not only be whether they are perfect, but whether they are materially better than what they might replace.

The anniversary tone surrounding the Framework Convention often suggests moral clarity and linear progress. There is a narrative of steady decline, cumulative success and righteous perseverance. Yet the data tell a more complicated story. Global prevalence has declined, but unevenly. Absolute numbers remain stubbornly high. In some settings, progress has plateaued. Illicit trade persists despite protocols aimed at its elimination.

Policy does not exist in a vacuum. It operates within social, economic and technological contexts that change. A framework that does not evolve risks defending its own legacy rather than re-examining its assumptions. That is not a criticism of the original treaty architects. They worked with the tools and evidence available at the time. It is a recognition that evidence-based policy must remain dynamic if it is to remain credible.

The ultimate benchmark is not institutional continuity but public health outcomes. The United Nations Sustainable Development Goals, particularly SDG3, focus on reducing premature mortality from non-communicable diseases. If the objective is fewer preventable deaths, then flexibility becomes a virtue rather than a weakness. Incorporating new evidence, new technologies and harm reduction strategies should not be seen as diluting the mission but as refining it.

Renewing commitment to a treaty is straightforward. Updating doctrine is harder. It requires acknowledging that some original assumptions may need adjustment. It requires separating moral opposition to an industry from empirical assessment of products. It requires distinguishing between nicotine use and smoke inhalation in ways that policy has historically resisted.

Anniversaries invite celebration. They should also invite reflection. Reflection means asking whether the blueprint still fits the building. If combustible cigarettes remain ubiquitous, if more than a billion people continue to smoke, and if innovation is reshaping the nicotine market regardless of regulatory preference, then the question is not whether the Framework Convention was important. It was. The question is whether it is sufficiently adaptable to meet the realities of the present.

Evidence-based policy cannot be a static label. It must be a process. If the goal is genuinely smoke-free societies and fewer preventable deaths, then the courage required now may not be the courage to repeat established orthodoxy, but the courage to revisit it.